This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Ye X, Reyes C, Hille J, Benn L, Lash S.Adverse effects and associated costs with 2nd- and 3rd-line therapies for non-small cell lung cancer. 13th World Conference on Lung Cancer: abstr. PD1.4.6, 31 Jul 2009. Available from: URL: http://www.2009worldlungcancer.org
Rights and permissions
About this article
Cite this article
Lower AEs and associated costs with erlotinib in NSCLC treatment. Pharmacoecon. Outcomes News 587, 7 (2009). https://doi.org/10.2165/00151234-200905870-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905870-00018